Convalescent Plasma Therapy: a Possible Treatment of COVID- 19 Pandemic
Abstract
COVID 19 is a newly recognized infectious disease that has rapidly
spread with no verified treatment available. It is caused by Severe
Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2). In
Convalescent plasma therapy, the yellowish liquid or the plasma
from the recovered blood is used to treat the patient suffering
from the same illness. For more than 100 years it has been used
to treat severe infections with varying degrees of success. For this
present infection, multiple clinical trials on plasma therapy are
still under vigorous investigations. Despite the very low chance
of risks like allergies, lung damage, and transmission of bloodrelated
infection, the therapy has shown a positive result in the
recovery of the patients. Many experts are observing its use as a
“stopgap measure” until effective vaccines and antiviral drugs are
available in a wide range. However, the main challenges faced are
finding suitable donors, its expensiveness in the whole procedure,
and inability to perform on a large scale. In this commentary,
summarization of the convalescent plasma therapy is done as a
hopeful alternative therapy of severe or critical COVID 19. It has
also emphasized the promising results shown since the past while
the use of this therapy in various infectious diseases.
Copyright (c) 2020 Author(s)
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles published in EJMS are licensed under the Creative Commons Attribution 4.0 International License (CC-BY 4.0). The author/s as the copyright holder will retain the ownership of the copyrights without restrictions for their content under the CC-BY 4.0 license, and allow others to copy, use, print, share, modify, and distribute the content of the article even in commercial purpose as long as the original authors and the journal are properly cited. No permission is required from the author/s or the publishers. Appropriate attribution can be provided by simply citing the original article.
On behalf of all the authors, the corresponding author is responsible for completing and returning the agreement form to the editorial office. More information about the terms and conditions, privacy policies, and copyrights can be found on the webpage of the Creative Commons license privacy policy. https://creativecommons.org/licenses/by/4.0/
